Abstract:Invasion and intrahepatic metastasis are major factors of poor prognosis in patients with hepatocellular carcinoma (HCC). In this study, we show that increased Src homolog and collagen homolog 3 (Shc3) expression in malignant HCC cell lines associate with HCC invasion and metastasis. Shc3 was significantly upregulated in tumors of 33 HCC patient samples as compared to adjacent normal tissues. Further analysis of 52 HCC patient samples showed that Shc3 expression correlated with microvascular invasion, cancer staging, and poor prognosis. Shc3 interacted with major vault protein (MVP), resulting in activation of MEK1/2 and ERK1/2 independently of Shc1 and c-Raf; this interaction consequently induced epithelialmesenchymal transition (EMT) and promoted HCC cell proliferation and metastasis. The observed increase in Shc3 levels was due to demethylation of its upstream promoter, which allowed c-Jun binding. In turn, Shc3 expression promoted c-Jun phosphorylation in a positive feedback loop. Analysis of metastasis using a tumor xenograft mouse model further confirmed the role of Shc3 in vivo. Taken together, our results indicate the importance of Shc3 in HCC progression and identify Shc3 as a novel biomarker and potential therapeutic target in HCC. Research. on January 13, 2018. © 2018 American Association for Cancer cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on January 12, 2018; DOI: 10.1158/0008-5472.CAN-17-2432

Supplemental Tables from Demethylation-Induced Overexpression of Shc3 Drives c-Raf–Independent Activation of MEK/ERK in HCC

Supplemental Material and Methods from Demethylation-Induced Overexpression of Shc3 Drives c-Raf–Independent Activation of MEK/ERK in HCC

Supplemental Figures from Demethylation-Induced Overexpression of Shc3 Drives C-Raf–independent Activation of MEK/ERK in HCC

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Data from Demethylation-Induced Overexpression of Shc3 Drives C-Raf–independent Activation of MEK/ERK in HCC

Demethylation-induced overexpression of Shc 3 drives c-Raf-independent activation of MEK / ERK in HCC Short Title : Shc 3 / MVP / MEK / ERK promotes HCC progress

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Tables from CBX8 Exhibits Oncogenic Activity Via AKT/β-Catenin Activation in Hepatocellular Carcinoma

Supplementary Table 1 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis

Supplementary Tables from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Table 1 from Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets

Supplemental Tables S1-4 from Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma

Supplemental Table S6-9 from Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma

Supplementary Table 1 from HAb18G/CD147 Promotes Pstat3-Mediated Pancreatic Cancer Development Via CD44s

Additional File 2 of Hepatocellular Carcinoma Detection Via Targeted Enzymatic Methyl Sequencing of Plasma Cell-Free DNA

Supplementary files from An LTR Retrotransposon-Derived Long Noncoding RNA lncMER52A Promotes Hepatocellular Carcinoma Progression by Binding p120-Catenin

Supplementary Tables from A Feedback Circuitry Between Polycomb Signaling and Fructose-1, 6-Bisphosphatase Enables Hepatic and Renal Tumorigenesis

Supplementary Table 1 from Targeting the Epigenetic Reader ENL Inhibits Super-Enhancer–Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression

Supplemental Table S5 from Genomic and Epigenomic Heterogeneity of Hepatocellular Carcinoma